<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>Evan Albright — Digest tagged &quot;business-models&quot;</title><description>Digest issues tagged #business-models.</description><link>https://www.evanalbright.com/</link><language>en-us</language><item><title>Claude returns from export control limbo as Cloudflare opens agent toll roads</title><link>https://www.evanalbright.com/digest/2026-07-02/</link><guid isPermaLink="true">https://www.evanalbright.com/digest/2026-07-02/</guid><description>Anthropic&apos;s Claude Sonnet 5 shipped on June 30 and Fable 5 returned globally on July 1 after the Department of Commerce lifted export controls that had restricted access for 19 days. Cloudflare declared a second Content Independence Day, launching a Monetization Gateway that lets site owners charge AI agents for any resource via stablecoin settlement over the x402 protocol, and released new granular controls to distinguish search bots from training bots. The FDA granted a historic clearance to an LLM-based diabetes management app, prompting debate about whether the model is an interface or a clinical decision-maker. Biotech stocks have now rallied for 15 consecutive months. The U.S. Department of Transportation proposed the first update to supersonic flight rules since the 1970s, opening the door to civilian supersonic travel.</description><pubDate>Thu, 02 Jul 2026 00:00:00 GMT</pubDate><category>ai</category><category>software</category><category>pharma</category><category>healthtech</category><category>economy</category><category>anthropic</category><category>claude</category><category>fda</category><category>clearance</category><category>llm</category><category>export-controls</category><category>agents</category><category>cloudflare</category><category>x402</category><category>stablecoin</category><category>drug-discovery</category><category>biotech</category><category>synthetic-biology</category><category>supersonic</category><category>rent-control</category><category>mental-health</category><category>open-weights</category><category>software-factory</category><category>housing</category><category>treasuries</category><category>bond-market</category><category>heat</category><category>public-health</category><category>vaccines</category><category>cdc</category><category>social-media</category><category>release</category><category>policy</category><category>code-generation</category><category>mit-license</category><category>jailbreak</category><category>safety</category><category>industry</category><category>self-improvement</category><category>research</category><category>developer-tools</category><category>coding</category><category>automation</category><category>human-ai</category><category>conference</category><category>diffusion</category><category>arxiv</category><category>open-science</category><category>nonprofit</category><category>preprints</category><category>google</category><category>gemini</category><category>image-models</category><category>inference</category><category>models</category><category>history</category><category>internet</category><category>infrastructure</category><category>security</category><category>android</category><category>malware</category><category>platforms</category><category>culture</category><category>glm</category><category>startups</category><category>search</category><category>platform</category><category>biology</category><category>synthetic</category><category>payments</category><category>crypto</category><category>analytics</category><category>content</category><category>business-models</category><category>monetization</category><category>ai-traffic</category><category>crawlers</category><category>web-economics</category><category>enterprise</category><category>software-engineering</category><category>agile</category><category>tdd</category><category>trust</category><category>isolation</category><category>playwright</category><category>video</category><category>apis</category><category>api</category><category>code-quality</category><category>cli</category><category>deployment</category><category>devops</category><category>observability</category><category>diabetes</category><category>regulation</category><category>stocks</category><category>investment</category><category>markets</category><category>biopharma</category><category>guidance</category><category>science</category><category>cell</category><category>obesity</category><category>cardiovascular</category><category>statins</category><category>clinical</category><category>gene-therapy</category><category>m&amp;a</category><category>turnaround</category><category>payer</category><category>climate</category><category>health</category><category>fitness</category><category>education</category><category>youth</category><category>chatbots</category><category>drugs</category><category>treatment</category><category>cells</category><category>drug-development</category><category>teens</category><category>risk</category><category>population</category><category>vaccine-effectiveness</category><category>drug-pricing</category><category>aviation</category><category>dot</category><category>transport</category><category>norway</category><category>economics</category><category>negativity</category><category>reddit</category><category>behavioral</category><category>jobs</category><category>glp-1</category><category>macroeconomics</category><category>labor</category><category>liquidity</category><category>fed</category><category>financial-markets</category><category>art</category><category>hardware</category><category>india</category><category>behavior</category><category>psychology</category><category>communication</category><category>information</category><category>books</category><category>narrative</category><category>evidence</category><category>geopolitics</category><category>resources</category><category>courts</category><category>politics</category><category>interview</category><category>democracy</category><category>prediction-markets</category><category>governance</category><category>equity</category><category>volatility</category><category>taxation</category><category>inequality</category><category>central-banking</category><category>crisis</category><category>microstructure</category><category>arbitrage</category><category>development</category></item><item><title>US suspends Fable 5 access for foreign nationals as export controls hit frontier AI</title><link>https://www.evanalbright.com/digest/2026-06-15/</link><guid isPermaLink="true">https://www.evanalbright.com/digest/2026-06-15/</guid><description>The US government issued an export control directive suspending all access to Claude Fable 5 and Mythos 5 for foreign nationals, a move that rattled the AI industry and prompted Tyler Cowen to note the equilibrium was hard to solve for. Separately, Arvind Narayanan and Sayash Kappoor published a detailed argument that software engineers won&apos;t be replaced by AI, citing task fragmentation and the compounding cost of errors. The FDA approved Sanofi&apos;s teplizumab for children with stage 3 type 1 diabetes after it cleared a dispute between career staff and political appointees. Noah Smith asked whether Chinese corporate debt could zombify the economy, while Patrick Boyle examined how SpaceX humiliated Wall Street by retaining founder control across 25x more fundraising than typical startups.</description><pubDate>Mon, 15 Jun 2026 00:00:00 GMT</pubDate><category>ai</category><category>software</category><category>pharma</category><category>healthtech</category><category>economy</category><category>claude</category><category>fable5</category><category>export-control</category><category>governance</category><category>policy</category><category>fda</category><category>drug-approval</category><category>spacex</category><category>ipo</category><category>china</category><category>prediction-markets</category><category>medicare</category><category>drug-shortage</category><category>llm</category><category>evals</category><category>agents</category><category>safety</category><category>syphilis</category><category>penicillin</category><category>medicaid</category><category>agi</category><category>software-engineering</category><category>jobs</category><category>economics</category><category>gdp</category><category>labor</category><category>macroeconomics</category><category>clinical</category><category>health-ai</category><category>benchmarks</category><category>education</category><category>training</category><category>nvidia</category><category>open-source</category><category>commoditization</category><category>analysis</category><category>trends</category><category>forecasting</category><category>rag</category><category>knowledge-graphs</category><category>reasoning</category><category>mlops</category><category>edge-ml</category><category>robotics</category><category>cnns</category><category>architecture</category><category>efficiency</category><category>cv</category><category>healthcare</category><category>applications</category><category>security</category><category>curl</category><category>engineering</category><category>apple</category><category>sdk</category><category>on-device</category><category>tools</category><category>provenance</category><category>formal-methods</category><category>programming</category><category>verification</category><category>codex</category><category>model-routing</category><category>reliability</category><category>cloudflare</category><category>kafka</category><category>postgres</category><category>scaling</category><category>performance</category><category>editor</category><category>productivity</category><category>tooling</category><category>drm</category><category>standards</category><category>epub</category><category>windows</category><category>authentication</category><category>user-experience</category><category>archival</category><category>web</category><category>finance</category><category>marketplace</category><category>auth</category><category>platform</category><category>storage</category><category>pricing</category><category>workflows</category><category>nitro</category><category>serverless</category><category>models</category><category>api</category><category>inference</category><category>collaboration</category><category>sharing</category><category>diabetes</category><category>pediatrics</category><category>sanofi</category><category>maternal-health</category><category>public-health</category><category>disability</category><category>caregivers</category><category>funding</category><category>ebola</category><category>who</category><category>drc</category><category>outbreak</category><category>crispr</category><category>gene-editing</category><category>obesity</category><category>cancer</category><category>drug-discovery</category><category>biotech</category><category>investment</category><category>abridge</category><category>drug-pricing</category><category>cms</category><category>history</category><category>nutrition</category><category>california</category><category>food</category><category>antibiotics</category><category>supply-chain</category><category>state-legislation</category><category>evidence</category><category>psychiatry</category><category>autism</category><category>stigma</category><category>medical-education</category><category>careers</category><category>demographics</category><category>hiring</category><category>industry</category><category>newsletter</category><category>venture-capital</category><category>musk</category><category>capital-markets</category><category>debt</category><category>corporate</category><category>growth</category><category>sports</category><category>regulation</category><category>betting</category><category>europe</category><category>brazil</category><category>agriculture</category><category>immigration</category><category>data</category><category>geopolitics</category><category>psychology</category><category>research</category><category>film</category><category>culture</category><category>cities</category><category>science</category><category>politics</category><category>links</category><category>roundup</category><category>philosophy</category><category>science-fiction</category><category>retail</category><category>service-sector</category><category>mexico</category><category>inflation</category><category>innovation</category><category>trade</category><category>strategy</category><category>bubbles</category><category>space</category><category>manufacturing</category><category>satellites</category><category>business-models</category></item></channel></rss>